NasdaqGM - Delayed Quote USD

XOMA Royalty Corporation (XOMAO)

25.00

-0.15

(-0.60%)

At close: May 2 at 4:00:00 PM EDT

High Growth Tech Stocks In The US To Watch April 2025

As the U.S. stock market rebounds from recent declines, with the Dow Jones surging over 1,000 points and tech-heavy indices like the Nasdaq Composite seeing significant gains, investors are closely monitoring high-growth tech stocks amid ongoing economic uncertainties such as tariff impacts and Federal Reserve dynamics. In this environment, identifying promising tech companies involves assessing their resilience to market volatility and their ability to capitalize on technological...

Simply Wall St. 11 days ago

XRX

XOMA

XOMAO
-0.60%
XOMA Royalty Corporation's (NASDAQ:XOMA) Path To Profitability

With the business potentially at an important milestone, we thought we'd take a closer look at XOMA Royalty...

Simply Wall St. 18 days ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty Completes Sale of Kinnate Pipeline Assets

XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggr

GlobeNewswire 19 days ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty Corporation (XOMA): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout

We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where XOMA Royalty Corporation (NASDAQ:XOMA) stands against other stocks that insiders bought in April after Trump’s tariff rollout. President Donald Trump called April 2 a “Liberation Day” after […]

Insider Monkey 24 days ago

XOMA
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025. Mr. Sitko’s presentation will take place on Wednesday, April 9, 2025, at 10:30 AM PT. The presentation can be assessed by visiting https://bit.ly/4l7bz6m. XOMA’s presentations can also be acce

GlobeNewswire last month

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B

GlobeNewswire last month

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty Full Year 2024 Earnings: EPS Misses Expectations

XOMA Royalty ( NASDAQ:XOMA ) Full Year 2024 Results Key Financial Results Revenue: US$28.5m (up 499% from FY 2023). Net...

Simply Wall St. last month

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day One’s OJEMDA™ (tovorafenib) and Zevra’s MIPLYFFA™ (arimoclomol) each received FDA approval Cash receipts totaled $4.0 million in the fourth quarter and $46.3 million for the full year 2024 EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA),

GlobeNewswire last month

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty Corporation's (NASDAQ:XOMA) largest shareholders are retail investors with 38% ownership, institutions own 36%

Key Insights The considerable ownership by retail investors in XOMA Royalty indicates that they collectively have a...

Simply Wall St. 2 months ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty to Present at Investor Conferences in March

EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meetings. T.D. Cowen 45th Annual Health Care Conference (March 3-5, 2025)Format:Date:Time:Corporate presentationMonday, March 3, 202511:10AM ETLocation:Link:Boston, MAhttps://bit.ly/4jUN9w2 Leerink 2025 Glo

GlobeNewswire 2 months ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually, February 11-12, 2025. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will participate in a fireside chat on Tuesday, February 11, 2025 at 3:20 PM ET. The presentation can be assessed by vi

GlobeNewswire 2 months ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc., and Chiesi Farmaceutici S.p.A; a Phase 3 study for pulmonary arterial hypertension is ongoing and is expected to read out in the fourth quarter of 20251 XOMA Royalty has the potential to net up to $25 million in milestone payments and earn a low to mid-single digit ro

GlobeNewswire 4 months ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
What Makes XOMA Royalty (XOMA) a New Buy Stock

XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 5 months ago

XOMA
XOMA Royalty Corporation (NASDAQ:XOMA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

XOMA Royalty Corporation ( NASDAQ:XOMA ) came out with its third-quarter results last week, and we wanted to see how...

Simply Wall St. 5 months ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

XOMA Royalty ( NASDAQ:XOMA ) Third Quarter 2024 Results Key Financial Results Revenue: US$7.20m (up by US$6.37m from 3Q...

Simply Wall St. 5 months ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates

XOMA Royalty (XOMA) delivered earnings and revenue surprises of 11.36% and 8.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

XOMA
XOMA Royalty: Q3 Earnings Snapshot

EMERYVILLE, Calif. AP) — XOMA Royalty Corporation (XOMA) on Thursday reported a loss of $18.6 million in its third quarter. The Emeryville, California-based company said it had a loss of $1.59 per share.

Associated Press Finance 5 months ago

XOMA
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s portfolio of 60-plus licensed early-stage assets across approximately 30 partners Cash receipts totaled $9.9 million in the third quarter, and $42.3 million for the first nine months of 2024 EMERYVILLE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty

GlobeNewswire 5 months ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all fut

GlobeNewswire 6 months ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%
Investors in XOMA Royalty (NASDAQ:XOMA) have seen favorable returns of 72% over the past year

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...

Simply Wall St. 6 months ago

XOMA

XOMAO
-0.60%

XOMAP
+0.51%

Performance Overview

Return	XOMAO	S&P 500 (^GSPC)
YTD	+1.54%	-3.31%
1-Year	+8.18%	+12.29%
3-Year	+25.83%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

XOMA Royalty Corporation (XOMAO)

High Growth Tech Stocks In The US To Watch April 2025

XOMA Royalty Corporation's (NASDAQ:XOMA) Path To Profitability

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

XOMA Royalty Corporation (XOMA): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Full Year 2024 Earnings: EPS Misses Expectations

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

XOMA Royalty Corporation's (NASDAQ:XOMA) largest shareholders are retail investors with 38% ownership, institutions own 36%

XOMA Royalty to Present at Investor Conferences in March

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

What Makes XOMA Royalty (XOMA) a New Buy Stock

XOMA Royalty Corporation (NASDAQ:XOMA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

XOMA Royalty Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates

XOMA Royalty: Q3 Earnings Snapshot

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Investors in XOMA Royalty (NASDAQ:XOMA) have seen favorable returns of 72% over the past year

Performance Overview